Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

46.78
-0.4700-0.99%
Volume:2.46M
Turnover:115.06M
Market Cap:7.77B
PE:-13.44
High:47.59
Open:47.20
Low:46.39
Close:47.25
52wk High:86.74
52wk Low:46.39
Shares:166.18M
Float Shares:161.92M
Volume Ratio:1.41
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:17.68
PE(LYR):-19.65

Loading ...

Movement Alert|Ionis Pharmaceuticals Falls 9.78% Overnight, Partner Novartis Pelacarsen Phase 3 Cardiovascular Outcomes Trial Fails to Meet Primary Endpoint

Market Focus
·
Sep 08

Citi sees limited immediate downside for Ionis after pelacarsen failure

TIPRANKS
·
Sep 07

Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex

Dow Jones
·
Sep 05

Ionis Pharmaceuticals Updates on Novartis Pelacarsen Trial Outcome

TIPRANKS
·
Sep 05

Novartis announces Phase 3 pelacarsen study did not meet primary endpoint

TIPRANKS
·
Sep 05

Ionis-Novartis Heart Drug Misses Main Goal of Late-Stage Trial

Reuters
·
Sep 05

Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint

Dow Jones
·
Sep 05

Ionis Pharmaceuticals: Buy Rating Backed by FDA Approval of Zanvastro and Strengthened Neurology Pipeline Upside

TIPRANKS
·
Sep 05

Movement Alert|Ionis Pharmaceuticals Falls 9.43% in After-Hours Trading, FDA Approval of Alexander Disease Drug Triggers Sell-the-News Reaction

Market Focus
·
Sep 05

Ionis Pharmaceuticals (IONS) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 05

This Biotech Wins a Big FDA Approval. Why Wall Street is Shrugging.

Dow Jones
·
Sep 05

Analysts’ Opinions Are Mixed on These Healthcare Stocks: cbdMD (YCBD) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Sep 04

Ionis Pharmaceuticals' Zanvastro Approval Sets Path for Independent Neurology Business, Oppenheimer Says

MT Newswires Live
·
Sep 04

Ionis Pharmaceuticals Exec Says Zanvastro Will be Available at List Price of $285,000 Per Dose

THOMSON REUTERS
·
Sep 04

U.S. Stocks on the MOVE-Lululemon Athletica, Adobe, Ionis Pharmaceuticals

Reuters
·
Sep 04

Ionis Pharmaceuticals (IONS) Receives a Hold from BMO Capital

TIPRANKS
·
Sep 04

Ionis Pharmaceuticals Price Target Maintained with a $115.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 04

Ionis Pharma up After US FDA Approves Rare Brain Disorder Treatment

Reuters
·
Sep 04

Ionis Pharmaceuticals Gets FDA Approval for Alexander Disease Treatment

MT Newswires Live
·
Sep 04

U.S. Research Roundup-Ciena Corp, Docusign, Snowflake

Reuters
·
Sep 04